Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV.
Identifieur interne : 001B75 ( PubMed/Checkpoint ); précédent : 001B74; suivant : 001B76Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV.
Auteurs : Kumari G. Lokugamage [États-Unis] ; Naoko Yoshikawa-Iwata ; Naoto Ito ; Douglas M. Watts ; Philip R. Wyde ; Nan Wang ; Patrick Newman ; Chien-Te Kent Tseng ; C J Peters ; Shinji MakinoSource :
- Vaccine [ 0264-410X ] ; 2008.
Descripteurs français
- KwdFr :
- Alignement de séquences, Animaux, Anticorps antiviraux (immunologie), Anticorps antiviraux (sang), Données de séquences moléculaires, Femelle, Glycoprotéine de spicule des coronavirus, Glycoprotéines membranaires (génétique), Glycoprotéines membranaires (métabolisme), Humains, Injections musculaires, Lignée cellulaire, Protéines de l'enveloppe virale (génétique), Protéines de l'enveloppe virale (métabolisme), Protéines de la matrice virale (métabolisme), Souris, Souris de lignée BALB C, Spécificité des anticorps, Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (sang), Syndrome respiratoire aigu sévère (virologie), Séquence d'acides aminés, Tests de neutralisation, Vaccination, Vaccins antiviraux (administration et posologie), Virus du SRAS (immunologie), Virus du SRAS (métabolisme), Virus recombinants (immunologie), Virus recombinants (métabolisme).
- MESH :
- administration et posologie : Vaccins antiviraux.
- génétique : Glycoprotéines membranaires, Protéines de l'enveloppe virale.
- immunologie : Anticorps antiviraux, Virus du SRAS, Virus recombinants.
- métabolisme : Glycoprotéines membranaires, Protéines de l'enveloppe virale, Protéines de la matrice virale, Virus du SRAS, Virus recombinants.
- sang : Anticorps antiviraux, Syndrome respiratoire aigu sévère.
- virologie : Syndrome respiratoire aigu sévère.
- Alignement de séquences, Animaux, Données de séquences moléculaires, Femelle, Glycoprotéine de spicule des coronavirus, Humains, Injections musculaires, Lignée cellulaire, Souris, Souris de lignée BALB C, Spécificité des anticorps, Syndrome respiratoire aigu sévère, Séquence d'acides aminés, Tests de neutralisation, Vaccination.
English descriptors
- KwdEn :
- Amino Acid Sequence, Animals, Antibodies, Viral (blood), Antibodies, Viral (immunology), Antibody Specificity, Cell Line, Female, Humans, Injections, Intramuscular, Membrane Glycoproteins (genetics), Membrane Glycoproteins (metabolism), Mice, Mice, Inbred BALB C, Molecular Sequence Data, Neutralization Tests, Reassortant Viruses (immunology), Reassortant Viruses (metabolism), SARS Virus (immunology), SARS Virus (metabolism), Sequence Alignment, Severe Acute Respiratory Syndrome (blood), Severe Acute Respiratory Syndrome (prevention & control), Severe Acute Respiratory Syndrome (virology), Spike Glycoprotein, Coronavirus, Vaccination, Viral Envelope Proteins (genetics), Viral Envelope Proteins (metabolism), Viral Matrix Proteins (metabolism), Viral Vaccines (administration & dosage).
- MESH :
- chemical , administration & dosage : Viral Vaccines.
- chemical , blood : Antibodies, Viral.
- chemical , genetics : Membrane Glycoproteins, Viral Envelope Proteins.
- chemical , immunology : Antibodies, Viral.
- chemical , metabolism : Membrane Glycoproteins, Viral Envelope Proteins, Viral Matrix Proteins.
- blood : Severe Acute Respiratory Syndrome.
- immunology : Reassortant Viruses, SARS Virus.
- metabolism : Reassortant Viruses, SARS Virus.
- prevention & control : Severe Acute Respiratory Syndrome.
- virology : Severe Acute Respiratory Syndrome.
- Amino Acid Sequence, Animals, Antibody Specificity, Cell Line, Female, Humans, Injections, Intramuscular, Mice, Mice, Inbred BALB C, Molecular Sequence Data, Neutralization Tests, Sequence Alignment, Spike Glycoprotein, Coronavirus, Vaccination.
Abstract
We tested the efficacy of coronavirus-like particles (VLPs) for protecting mice against severe acute respiratory syndrome coronavirus (SCoV) infection. Coexpression of SCoV S protein and E, M and N proteins of mouse hepatitis virus in 293T or CHO cells resulted in the efficient production of chimeric VLPs carrying SCoV S protein. Balb/c mice inoculated with a mixture of chimeric VLPs and alum twice at an interval of four weeks were protected from SCoV challenge, as indicated by the absence of infectious virus in the lungs. The same groups of mice had high levels of SCoV-specific neutralizing antibodies, while mice in the negative control groups, which were not immunized with chimeric VLPs, failed to manifest neutralizing antibodies, suggesting that SCoV-specific neutralizing antibodies are important for the suppression of viral replication within the lungs. Despite some differences in the cellular composition of inflammatory infiltrates, we did not observe any overt lung pathology in the chimeric-VLP-treated mice, when compared to the negative control mice. Our results show that chimeric VLP can be an effective vaccine strategy against SCoV infection.
DOI: 10.1016/j.vaccine.2007.11.092
PubMed: 18191004
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:18191004Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV.</title><author><name sortKey="Lokugamage, Kumari G" sort="Lokugamage, Kumari G" uniqKey="Lokugamage K" first="Kumari G" last="Lokugamage">Kumari G. Lokugamage</name><affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Yoshikawa Iwata, Naoko" sort="Yoshikawa Iwata, Naoko" uniqKey="Yoshikawa Iwata N" first="Naoko" last="Yoshikawa-Iwata">Naoko Yoshikawa-Iwata</name></author><author><name sortKey="Ito, Naoto" sort="Ito, Naoto" uniqKey="Ito N" first="Naoto" last="Ito">Naoto Ito</name></author><author><name sortKey="Watts, Douglas M" sort="Watts, Douglas M" uniqKey="Watts D" first="Douglas M" last="Watts">Douglas M. Watts</name></author><author><name sortKey="Wyde, Philip R" sort="Wyde, Philip R" uniqKey="Wyde P" first="Philip R" last="Wyde">Philip R. Wyde</name></author><author><name sortKey="Wang, Nan" sort="Wang, Nan" uniqKey="Wang N" first="Nan" last="Wang">Nan Wang</name></author><author><name sortKey="Newman, Patrick" sort="Newman, Patrick" uniqKey="Newman P" first="Patrick" last="Newman">Patrick Newman</name></author><author><name sortKey="Kent Tseng, Chien Te" sort="Kent Tseng, Chien Te" uniqKey="Kent Tseng C" first="Chien-Te" last="Kent Tseng">Chien-Te Kent Tseng</name></author><author><name sortKey="Peters, C J" sort="Peters, C J" uniqKey="Peters C" first="C J" last="Peters">C J Peters</name></author><author><name sortKey="Makino, Shinji" sort="Makino, Shinji" uniqKey="Makino S" first="Shinji" last="Makino">Shinji Makino</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2008">2008</date><idno type="RBID">pubmed:18191004</idno><idno type="pmid">18191004</idno><idno type="doi">10.1016/j.vaccine.2007.11.092</idno><idno type="wicri:Area/PubMed/Corpus">001C37</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001C37</idno><idno type="wicri:Area/PubMed/Curation">001C37</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001C37</idno><idno type="wicri:Area/PubMed/Checkpoint">001B75</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001B75</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV.</title><author><name sortKey="Lokugamage, Kumari G" sort="Lokugamage, Kumari G" uniqKey="Lokugamage K" first="Kumari G" last="Lokugamage">Kumari G. Lokugamage</name><affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Yoshikawa Iwata, Naoko" sort="Yoshikawa Iwata, Naoko" uniqKey="Yoshikawa Iwata N" first="Naoko" last="Yoshikawa-Iwata">Naoko Yoshikawa-Iwata</name></author><author><name sortKey="Ito, Naoto" sort="Ito, Naoto" uniqKey="Ito N" first="Naoto" last="Ito">Naoto Ito</name></author><author><name sortKey="Watts, Douglas M" sort="Watts, Douglas M" uniqKey="Watts D" first="Douglas M" last="Watts">Douglas M. Watts</name></author><author><name sortKey="Wyde, Philip R" sort="Wyde, Philip R" uniqKey="Wyde P" first="Philip R" last="Wyde">Philip R. Wyde</name></author><author><name sortKey="Wang, Nan" sort="Wang, Nan" uniqKey="Wang N" first="Nan" last="Wang">Nan Wang</name></author><author><name sortKey="Newman, Patrick" sort="Newman, Patrick" uniqKey="Newman P" first="Patrick" last="Newman">Patrick Newman</name></author><author><name sortKey="Kent Tseng, Chien Te" sort="Kent Tseng, Chien Te" uniqKey="Kent Tseng C" first="Chien-Te" last="Kent Tseng">Chien-Te Kent Tseng</name></author><author><name sortKey="Peters, C J" sort="Peters, C J" uniqKey="Peters C" first="C J" last="Peters">C J Peters</name></author><author><name sortKey="Makino, Shinji" sort="Makino, Shinji" uniqKey="Makino S" first="Shinji" last="Makino">Shinji Makino</name></author></analytic><series><title level="j">Vaccine</title><idno type="ISSN">0264-410X</idno><imprint><date when="2008" type="published">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amino Acid Sequence</term><term>Animals</term><term>Antibodies, Viral (blood)</term><term>Antibodies, Viral (immunology)</term><term>Antibody Specificity</term><term>Cell Line</term><term>Female</term><term>Humans</term><term>Injections, Intramuscular</term><term>Membrane Glycoproteins (genetics)</term><term>Membrane Glycoproteins (metabolism)</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Molecular Sequence Data</term><term>Neutralization Tests</term><term>Reassortant Viruses (immunology)</term><term>Reassortant Viruses (metabolism)</term><term>SARS Virus (immunology)</term><term>SARS Virus (metabolism)</term><term>Sequence Alignment</term><term>Severe Acute Respiratory Syndrome (blood)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>Spike Glycoprotein, Coronavirus</term><term>Vaccination</term><term>Viral Envelope Proteins (genetics)</term><term>Viral Envelope Proteins (metabolism)</term><term>Viral Matrix Proteins (metabolism)</term><term>Viral Vaccines (administration & dosage)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Alignement de séquences</term><term>Animaux</term><term>Anticorps antiviraux (immunologie)</term><term>Anticorps antiviraux (sang)</term><term>Données de séquences moléculaires</term><term>Femelle</term><term>Glycoprotéine de spicule des coronavirus</term><term>Glycoprotéines membranaires (génétique)</term><term>Glycoprotéines membranaires (métabolisme)</term><term>Humains</term><term>Injections musculaires</term><term>Lignée cellulaire</term><term>Protéines de l'enveloppe virale (génétique)</term><term>Protéines de l'enveloppe virale (métabolisme)</term><term>Protéines de la matrice virale (métabolisme)</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Spécificité des anticorps</term><term>Syndrome respiratoire aigu sévère ()</term><term>Syndrome respiratoire aigu sévère (sang)</term><term>Syndrome respiratoire aigu sévère (virologie)</term><term>Séquence d'acides aminés</term><term>Tests de neutralisation</term><term>Vaccination</term><term>Vaccins antiviraux (administration et posologie)</term><term>Virus du SRAS (immunologie)</term><term>Virus du SRAS (métabolisme)</term><term>Virus recombinants (immunologie)</term><term>Virus recombinants (métabolisme)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Membrane Glycoproteins</term><term>Viral Envelope Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Membrane Glycoproteins</term><term>Viral Envelope Proteins</term><term>Viral Matrix Proteins</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antiviraux</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Glycoprotéines membranaires</term><term>Protéines de l'enveloppe virale</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term><term>Virus du SRAS</term><term>Virus recombinants</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Reassortant Viruses</term><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Reassortant Viruses</term><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Glycoprotéines membranaires</term><term>Protéines de l'enveloppe virale</term><term>Protéines de la matrice virale</term><term>Virus du SRAS</term><term>Virus recombinants</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Amino Acid Sequence</term><term>Animals</term><term>Antibody Specificity</term><term>Cell Line</term><term>Female</term><term>Humans</term><term>Injections, Intramuscular</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Molecular Sequence Data</term><term>Neutralization Tests</term><term>Sequence Alignment</term><term>Spike Glycoprotein, Coronavirus</term><term>Vaccination</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Alignement de séquences</term><term>Animaux</term><term>Données de séquences moléculaires</term><term>Femelle</term><term>Glycoprotéine de spicule des coronavirus</term><term>Humains</term><term>Injections musculaires</term><term>Lignée cellulaire</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Spécificité des anticorps</term><term>Syndrome respiratoire aigu sévère</term><term>Séquence d'acides aminés</term><term>Tests de neutralisation</term><term>Vaccination</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We tested the efficacy of coronavirus-like particles (VLPs) for protecting mice against severe acute respiratory syndrome coronavirus (SCoV) infection. Coexpression of SCoV S protein and E, M and N proteins of mouse hepatitis virus in 293T or CHO cells resulted in the efficient production of chimeric VLPs carrying SCoV S protein. Balb/c mice inoculated with a mixture of chimeric VLPs and alum twice at an interval of four weeks were protected from SCoV challenge, as indicated by the absence of infectious virus in the lungs. The same groups of mice had high levels of SCoV-specific neutralizing antibodies, while mice in the negative control groups, which were not immunized with chimeric VLPs, failed to manifest neutralizing antibodies, suggesting that SCoV-specific neutralizing antibodies are important for the suppression of viral replication within the lungs. Despite some differences in the cellular composition of inflammatory infiltrates, we did not observe any overt lung pathology in the chimeric-VLP-treated mice, when compared to the negative control mice. Our results show that chimeric VLP can be an effective vaccine strategy against SCoV infection.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18191004</PMID><DateCompleted><Year>2008</Year><Month>05</Month><Day>09</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0264-410X</ISSN><JournalIssue CitedMedium="Print"><Volume>26</Volume><Issue>6</Issue><PubDate><Year>2008</Year><Month>Feb</Month><Day>06</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV.</ArticleTitle><Pagination><MedlinePgn>797-808</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2007.11.092</ELocationID><Abstract><AbstractText>We tested the efficacy of coronavirus-like particles (VLPs) for protecting mice against severe acute respiratory syndrome coronavirus (SCoV) infection. Coexpression of SCoV S protein and E, M and N proteins of mouse hepatitis virus in 293T or CHO cells resulted in the efficient production of chimeric VLPs carrying SCoV S protein. Balb/c mice inoculated with a mixture of chimeric VLPs and alum twice at an interval of four weeks were protected from SCoV challenge, as indicated by the absence of infectious virus in the lungs. The same groups of mice had high levels of SCoV-specific neutralizing antibodies, while mice in the negative control groups, which were not immunized with chimeric VLPs, failed to manifest neutralizing antibodies, suggesting that SCoV-specific neutralizing antibodies are important for the suppression of viral replication within the lungs. Despite some differences in the cellular composition of inflammatory infiltrates, we did not observe any overt lung pathology in the chimeric-VLP-treated mice, when compared to the negative control mice. Our results show that chimeric VLP can be an effective vaccine strategy against SCoV infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lokugamage</LastName><ForeName>Kumari G</ForeName><Initials>KG</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshikawa-Iwata</LastName><ForeName>Naoko</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Naoto</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Watts</LastName><ForeName>Douglas M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Wyde</LastName><ForeName>Philip R</ForeName><Initials>PR</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Nan</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Newman</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Kent Tseng</LastName><ForeName>Chien-Te</ForeName><Initials>CT</Initials></Author><Author ValidYN="Y"><LastName>Peters</LastName><ForeName>C J</ForeName><Initials>CJ</Initials></Author><Author ValidYN="Y"><LastName>Makino</LastName><ForeName>Shinji</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI072493-01A1</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AI72493</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AI 65298</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01AI65298</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI072493</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AI29984</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AI029984</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI029984</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI029984-16</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>12</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C501689">E protein, SARS coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578553">MHV surface projection glycoprotein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014763">Viral Matrix Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578557">spike glycoprotein, SARS-CoV</NameOfSubstance></Chemical><Chemical><RegistryNumber>108502-71-2</RegistryNumber><NameOfSubstance UI="C067997">M protein, Coronavirus</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000918" MajorTopicYN="N">Antibody Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007273" MajorTopicYN="N">Injections, Intramuscular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016865" MajorTopicYN="N">Reassortant Viruses</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016415" MajorTopicYN="N">Sequence Alignment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="Y">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014763" MajorTopicYN="N">Viral Matrix Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>10</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2007</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>1</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>5</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>1</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18191004</ArticleId><ArticleId IdType="pii">S0264-410X(07)01432-6</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2007.11.092</ArticleId><ArticleId IdType="pmc">PMC2267761</ArticleId><ArticleId IdType="mid">NIHMS39182</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lancet. 2004 Jun 26;363(9427):2139-41</Citation><ArticleIdList><ArticleId IdType="pubmed">15220038</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2001 Jan 20;279(2):371-4</Citation><ArticleIdList><ArticleId IdType="pubmed">11162792</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1999 Sep;73(9):7441-52</Citation><ArticleIdList><ArticleId IdType="pubmed">10438834</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2004 Jul 1;324(2):510-24</Citation><ArticleIdList><ArticleId IdType="pubmed">15207636</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Cell Biol. 1995 Oct;131(2):339-49</Citation><ArticleIdList><ArticleId IdType="pubmed">7593163</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):797-801</Citation><ArticleIdList><ArticleId IdType="pubmed">15642942</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2005 Sep 30;340(2):174-82</Citation><ArticleIdList><ArticleId IdType="pubmed">16043204</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2536-41</Citation><ArticleIdList><ArticleId IdType="pubmed">14983044</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2003 Apr;77(8):4528-38</Citation><ArticleIdList><ArticleId IdType="pubmed">12663759</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2005 Feb;79(3):1906-10</Citation><ArticleIdList><ArticleId IdType="pubmed">15650214</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1998 Nov;72(11):8636-43</Citation><ArticleIdList><ArticleId IdType="pubmed">9765403</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1948-51</Citation><ArticleIdList><ArticleId IdType="pubmed">12748314</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2003 Aug;77(16):9084-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12885925</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2007 Feb;81(3):1162-73</Citation><ArticleIdList><ArticleId IdType="pubmed">17108019</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2005 Mar;79(5):2678-88</Citation><ArticleIdList><ArticleId IdType="pubmed">15708987</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Comp Immunol Microbiol Infect Dis. 1981;4(2):175-89</Citation><ArticleIdList><ArticleId IdType="pubmed">6754243</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2001 Oct;75(19):9059-67</Citation><ArticleIdList><ArticleId IdType="pubmed">11533169</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2006 Jan 30;24(5):652-61</Citation><ArticleIdList><ArticleId IdType="pubmed">16214268</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1999 Sep;73(9):7752-60</Citation><ArticleIdList><ArticleId IdType="pubmed">10438865</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2006 Sep 15;353(1):6-16</Citation><ArticleIdList><ArticleId IdType="pubmed">16793110</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1990 Jun;64(6):2788-95</Citation><ArticleIdList><ArticleId IdType="pubmed">2159544</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Immunol Lett. 2004 Sep;95(2):139-43</Citation><ArticleIdList><ArticleId IdType="pubmed">15388253</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1992 Nov;66(11):6695-705</Citation><ArticleIdList><ArticleId IdType="pubmed">1383568</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9804-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15210961</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Immunology. 2007 Dec;122(4):496-502</Citation><ArticleIdList><ArticleId IdType="pubmed">17680799</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>EMBO J. 2005 Apr 20;24(8):1634-43</Citation><ArticleIdList><ArticleId IdType="pubmed">15791205</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 2005 Feb 15;191(4):507-14</Citation><ArticleIdList><ArticleId IdType="pubmed">15655773</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>FEBS Lett. 2004 Oct 8;576(1-2):174-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15474033</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2006 Jun;80(12):5757-67</Citation><ArticleIdList><ArticleId IdType="pubmed">16731915</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2005 May 25;23(28):3649-56</Citation><ArticleIdList><ArticleId IdType="pubmed">15882525</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 2006 Mar 1;193(5):685-92</Citation><ArticleIdList><ArticleId IdType="pubmed">16453264</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Methods. 2006 Sep;40(1):60-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16997714</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2000 Sep;74(17):8127-34</Citation><ArticleIdList><ArticleId IdType="pubmed">10933723</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Adv Virus Res. 2006;66:193-292</Citation><ArticleIdList><ArticleId IdType="pubmed">16877062</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>EMBO J. 1996 Apr 15;15(8):2020-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8617249</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2000 Feb;74(3):1566-71</Citation><ArticleIdList><ArticleId IdType="pubmed">10627571</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2006 Aug;80(15):7287-94</Citation><ArticleIdList><ArticleId IdType="pubmed">16840309</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1990 Mar;64(3):1407-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2154621</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Trends Microbiol. 2003 Sep;11(9):438-44</Citation><ArticleIdList><ArticleId IdType="pubmed">13678860</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Infect Immun. 2003 Aug;71(8):4536-43</Citation><ArticleIdList><ArticleId IdType="pubmed">12874333</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2007 Apr;81(8):4012-20</Citation><ArticleIdList><ArticleId IdType="pubmed">17267506</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2005 Mar 18;23(17-18):2273-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15755610</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2002 May;76(10):4987-99</Citation><ArticleIdList><ArticleId IdType="pubmed">11967315</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2003 Apr;77(8):4972-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12663803</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2004 Apr;78(7):3572-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15016880</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2005 Mar;79(6):3289-96</Citation><ArticleIdList><ArticleId IdType="pubmed">15731223</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Rev Immunol. 2005 Dec;5(12):917-27</Citation><ArticleIdList><ArticleId IdType="pubmed">16322745</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2007 Apr 12;25(15):2832-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17092615</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2007 Jan;81(2):813-21</Citation><ArticleIdList><ArticleId IdType="pubmed">17079315</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS Med. 2006 Dec;3(12):e525</Citation><ArticleIdList><ArticleId IdType="pubmed">17194199</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1997 Dec;71(12):9278-84</Citation><ArticleIdList><ArticleId IdType="pubmed">9371586</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2005 Nov;79(22):13915-23</Citation><ArticleIdList><ArticleId IdType="pubmed">16254327</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2006 Apr;80(8):4079-87</Citation><ArticleIdList><ArticleId IdType="pubmed">16571824</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>BMC Immunol. 2006 Oct 31;7:25</Citation><ArticleIdList><ArticleId IdType="pubmed">17076905</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2000 Feb;74(3):1393-406</Citation><ArticleIdList><ArticleId IdType="pubmed">10627550</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2005 Mar;79(6):3401-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15731234</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2004 Sep;78(18):9904-17</Citation><ArticleIdList><ArticleId IdType="pubmed">15331724</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6641-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15096611</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2005 Apr 10;334(2):160-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15780866</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 1999 Oct 25;263(2):265-72</Citation><ArticleIdList><ArticleId IdType="pubmed">10544100</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2005 May;79(10):5900-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15857975</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1999 Sep;73(9):7607-18</Citation><ArticleIdList><ArticleId IdType="pubmed">10438851</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2005 Apr 10;334(2):306-18</Citation><ArticleIdList><ArticleId IdType="pubmed">15780881</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2003 Oct 30;425(6961):915</Citation><ArticleIdList><ArticleId IdType="pubmed">14586458</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2005 Oct 10;23(42):4959-68</Citation><ArticleIdList><ArticleId IdType="pubmed">15993989</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2007 May 25;362(1):26-37</Citation><ArticleIdList><ArticleId IdType="pubmed">17258782</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2004 Apr 1;428(6982):561-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15024391</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 1999 Apr 9;17(15-16):1869-82</Citation><ArticleIdList><ArticleId IdType="pubmed">10217584</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2004 Nov;78(22):12557-65</Citation><ArticleIdList><ArticleId IdType="pubmed">15507643</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1980 Jan;33(1):449-62</Citation><ArticleIdList><ArticleId IdType="pubmed">6245243</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2005 Jan;79(1):503-11</Citation><ArticleIdList><ArticleId IdType="pubmed">15596843</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2007 Jul;81(14):7410-23</Citation><ArticleIdList><ArticleId IdType="pubmed">17507479</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2003 Mar;77(5):2922-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12584316</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>DNA Cell Biol. 2004 Jun;23(6):391-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15231072</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2430-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15695582</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1992 Feb;66(2):956-65</Citation><ArticleIdList><ArticleId IdType="pubmed">1309922</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Med. 2004 Dec;10(12 Suppl):S88-97</Citation><ArticleIdList><ArticleId IdType="pubmed">15577937</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nucleic Acids Res. 1994 Nov 11;22(22):4673-80</Citation><ArticleIdList><ArticleId IdType="pubmed">7984417</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Dec 10;325(2):445-52</Citation><ArticleIdList><ArticleId IdType="pubmed">15530413</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Texas</li></region></list><tree><noCountry><name sortKey="Ito, Naoto" sort="Ito, Naoto" uniqKey="Ito N" first="Naoto" last="Ito">Naoto Ito</name><name sortKey="Kent Tseng, Chien Te" sort="Kent Tseng, Chien Te" uniqKey="Kent Tseng C" first="Chien-Te" last="Kent Tseng">Chien-Te Kent Tseng</name><name sortKey="Makino, Shinji" sort="Makino, Shinji" uniqKey="Makino S" first="Shinji" last="Makino">Shinji Makino</name><name sortKey="Newman, Patrick" sort="Newman, Patrick" uniqKey="Newman P" first="Patrick" last="Newman">Patrick Newman</name><name sortKey="Peters, C J" sort="Peters, C J" uniqKey="Peters C" first="C J" last="Peters">C J Peters</name><name sortKey="Wang, Nan" sort="Wang, Nan" uniqKey="Wang N" first="Nan" last="Wang">Nan Wang</name><name sortKey="Watts, Douglas M" sort="Watts, Douglas M" uniqKey="Watts D" first="Douglas M" last="Watts">Douglas M. Watts</name><name sortKey="Wyde, Philip R" sort="Wyde, Philip R" uniqKey="Wyde P" first="Philip R" last="Wyde">Philip R. Wyde</name><name sortKey="Yoshikawa Iwata, Naoko" sort="Yoshikawa Iwata, Naoko" uniqKey="Yoshikawa Iwata N" first="Naoko" last="Yoshikawa-Iwata">Naoko Yoshikawa-Iwata</name></noCountry><country name="États-Unis"><region name="Texas"><name sortKey="Lokugamage, Kumari G" sort="Lokugamage, Kumari G" uniqKey="Lokugamage K" first="Kumari G" last="Lokugamage">Kumari G. Lokugamage</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B75 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001B75 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:18191004
|texte= Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:18191004" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |